Peritoneal Surface Disease from Colorectal Cancer: Comparison with the Hepatic Metastases Surgical Paradigm in Optimally Resected Patients

• Published in: Annals of surgical oncology 2008-12, Vol.15 (12), p.3422-3432
• Main Authors: Shen, Perry, Thai, Kurt, Stewart, John H., Howerton, Russell, Loggie, Brian W., Russell, Gregory B., Levine, Edward A.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - pathology; Colorectal Neoplasms - surgery; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Hyperthermia, Induced; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Liver Neoplasms - surgery; Male; Medicine; Medicine & Public Health; Middle Aged; Morbidity; Oncology; Other; Peritoneal Neoplasms - drug therapy; Peritoneal Neoplasms - secondary; Peritoneal Neoplasms - surgery; Postoperative Complications; Prognosis; Prospective Studies; Surgery; Surgical Oncology; Survival Rate; Treatment Outcome; Young Adult
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-008-0127-4

Background Surgical resection is the treatment of choice for colorectal hepatic metastases (HM). In contrast, metastatic disease to the peritoneum is treated with systemic therapy. We examined our experience with cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal surface disease (PSD) compared with liver resection for HM. Methods A review of prospective databases of colorectal cancer patients undergoing surgery for metastatic disease to the peritoneum or liver (1992–2005) was carried out. Results One hundred and twenty-one patients underwent CS + IPHC and 101 patients underwent hepatic resection with median follow-up of 86 and 56 months, respectively. Fifty-five (45%) patients in the IPHC group had complete resection of all gross tumor. Ninety-five (94%) of the HM patients had negative surgical margins. Comparison of the R0/R1 PSD and margin-negative HM group demonstrated significant differences in age, performance status, and preoperative chemotherapy. The 1-, 3-, and 5-year overall survival for the R0/R1 PSD patients was 91, 48, and 26%; while it was 87, 59, and 34% for the HM patients ( P  = 0.32). Perioperative morbidity was 42% versus 34% ( P  = 0.38) and mortality was 5.5% versus 4.2% ( P  = 0.71) between the PSD and HM patients, respectively. Conclusion R0/R1 resection during CS + IPHC compared with margin-negative hepatic resection demonstrated no significant difference in overall survival and for select patients should be considered a viable treatment option. Further studies to improve the resectability of PSD patients and define the role of neoadjuvant and adjuvant drug strategies are needed.